Primary objective:
- To investigate the microbiological efficacy, assessed as eradication rate based on
microbiologically evaluable patients 1 month post treatment with oral Levofloxacin 500
mg in male adults with chronic bacterial prostatitis (CBP, category II)
Secondary objectives:
- To investigate the microbiological efficacy, assessed as eradication rate based on
microbiologically evaluable patients 6 months post treatment with oral Levofloxacin 500
mg in male adults with chronic bacterial prostatitis (CBP, category II).
- To assess the clinical response rate based on resolution of signs and symptoms after 2
weeks of treatment; 5-12 days, 1 month, 3 months and 6 months post treatment with oral
Levofloxacin 500 mg in male adults with chronic bacterial prostatitis (CBP, category
II).
- To assess the safety of Levofloxacin 500 mg on the basis of adverse events, standard
clinical chemistry, hematology, urinalysis and vital signs in male adults with chronic
bacterial prostatitis (CBP, category II).